Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications CNS cancer; Eye neoplasms; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 15 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2019.
- 15 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.